Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19

Abstract

The recent outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China has spread rapidly around the world, leading to a widespread and urgent effort to develop and use comprehensive approaches in the treatment of COVID-19. While oral therapy is accepted as an effective and simple method, since the primary site of infection and disease progression of COVID-19 is mainly through the lungs, inhaled drug delivery directly to the lungs may be the most appropriate route of administration. To prevent or treat primary SARS-CoV-2 infections, it is essential to target the virus port of entry in the respiratory tract and airway epithelium, which requires rapid and high-intensity inhibition or control of viral entry or replication. To achieve success in this field, inhalation therapy is the most attractive treatment approach due to efficacy/safety profiles. In this review article, pulmonary drug delivery as a unique treatment option in lung diseases will be briefly reviewed. Then, possible inhalation therapies for the treatment of symptoms of COVID-19 will be discussed and the results of clinical trials will be presented. By pulmonary delivery of the currently approved drugs for COVID-19, efficacy of the treatment would be improved along with reducing systemic side effects. Graphical abstract

Stem Cell Extracellular Vesicles as Anti-SARS-CoV-2 Immunomodulatory Therapeutics: A Systematic Review of Clinical and Preclinical Studies

“…Finally, the mode of EV administration is dependent on the disease’s severity, where IV is usually selected for direct and faster drug delivery into the bloodstream in severe COVID-19 cases. In contrast, oral route is often used in early COVID-19 patients when there is a need for effective and economical treatment that can be taken at home [ 114 , 115 ]. However, the route of administration is also dependent on the drug properties, and the patient’s individual circumstances.…”

Pulmonary Diseases in Older Patients: Understanding and Addressing the Challenges

“…In the realm of COPD management, the appropriate delivery of medications and the mitigation of potential side effects are pivotal considerations. Tailoring drug delivery methods to suit individual patient needs ensures optimal efficacy while minimizing adverse reactions [ 28 , 31 , 32 , 33 , 34 ]. By focusing on these essential aspects, healthcare providers can significantly enhance the lives of COPD patients, mitigating the impact of this challenging condition on the older population.…”

Pulmonary inhalation for disease treatment: Basic research and clinical translations

“…Pulmonary inhalation is a promising treatment option for this disease owing to its efficacy and safety. It is believed that hydroxychloroquine (HCQ) and chloroquine (CQ) impede viral terminal glycosylation of ACE2; however, they do not alter ACE2 in mammalian cells; therefore, they might theoretically be used to treat neo-crown pneumonia [ 268 ]. Studies have shown that HCQ inhalation is safe and effectively tolerated [ 269 ].…”